EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates of Acinetobacter baumannii

Samir H Moussa iD, Adam B Shapiro iD, Sarah M McLeod iD, Ramkumar Iyer iD, Nicole M Carter iD, Yu-Kuo Tsai, L Kristopher Siu iD, Alita A Miller iD

Antimicrobial Agents and Chemotherapy · 15.11.2023 · 67 (11)

DOI: 10.1128/aac.00665-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 15.11.2023. Verfasst von Samir H Moussa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Innoviva Specialty Therapeutics Inc., an affiliate of Entasis Therapeutics Inc. , Waltham, Massachusetts, USA. Hauptthemen laut MEDLINE: Sulbactam, Acinetobacter baumannii. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acinetobacter baumannii - calcoaceticus complex (ABC) causes severe infections that are difficult to treat due to pre-existing antibiotic resistance. Sulbactam-durlobactam (SUL-DUR) is a targeted β-lactam/β-lactamase inhibitor combination antibiotic designed to treat serious infections caused by Acinetobacter , including multidrug- and carbapenem-resistant strains. In a recent global surveillance study of 5,032 ABC clinical isolates collected from 2016 to 2021, less than 2% of ABC isolates had SUL-DUR MIC values >4 µg/mL. Molecular characterization of these isolates confirmed the primary drivers of resistance are metallo-β-lactamases or penicillin-binding protein 3 (PBP3) mutations, as previously described. In addition, this study shows that certain common PBP3 variants, such as A515V, are insufficient to confer sulbactam resistance and that the efflux of durlobactam by AdeIJK is likely to play a role in a subset of strains.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SulbactamAcinetobacter baumanniiAnti-Bacterial AgentsAzabicyclo Compoundsbeta-Lactamase InhibitorsMonobactamsMicrobial Sensitivity TestsDrug Combinations

Stichwörter der Autor:innen

AcinetobacterETX2514durlobactamresistancesulbactamsurveillance studies

Substanzen

SulbactamAnti-Bacterial AgentsAzabicyclo Compoundsbeta-Lactamase InhibitorsMonobactamssulbactam-durlobactamDrug Combinations

Autor:innen und Institutionen

  • Innoviva Specialty Therapeutics Inc., an affiliate of Entasis Therapeutics Inc. , Waltham, Massachusetts, USA.
  • Kemyth Biotech Co., Ltd. , Taipei City, Taiwan.

ORCID-Profile: Samir H Moussa, Adam B Shapiro, Sarah M McLeod, Ramkumar Iyer, Nicole M Carter, L Kristopher Siu, Alita A Miller

Zitieren

APA

Moussa, S. H., Shapiro, A. B., McLeod, S. M., Iyer, R., Carter, N. M., Tsai, Y. K., Siu, L. K., & Miller, A. A. (2023). Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates of Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 67(11). https://doi.org/10.1128/aac.00665-23

Vancouver

Moussa SH, Shapiro AB, McLeod SM, Iyer R, Carter NM, Tsai YK, et al. Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates of Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy. 2023;67(11). doi:10.1128/aac.00665-23

BibTeX
@article{Moussa2023,
  author = {Moussa, Samir H and Shapiro, Adam B and McLeod, Sarah M and Iyer, Ramkumar and Carter, Nicole M and Tsai, Yu-Kuo and Siu, L Kristopher and Miller, Alita A},
  title = {Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates of Acinetobacter baumannii},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2023},
  volume = {67},
  number = {11},
  doi = {10.1128/aac.00665-23}
}
Kostenlos starten →